Marlene Bultemeyer, MD
Neurology · Fort Wayne, INNPI 1083828719
Payments from drug & device makers
Across 1,625 payments — averaging $323.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$135K
- Ipsen Innovation$110K
- AbbVie$91K
- Teva Pharmaceuticals USA, Inc.$50K
- SK Life Science, Inc.$44K
- Eisai Inc.$34K
- plus $61K from 54 others
What the payments were for
- Consulting fees$23,5889%
- Speaking & faculty fees$214,47177%
- Travel & lodging$12,9465%
- Food & beverage$25,3779%
- Education$4620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$85,157
- XCOPRI$36,732
- QULIPTA$31,562
- AJOVY$22,945
- Leqembi$20,887
- Austedo XR$14,622
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$12,352
- VYVGART$11,218
- AUSTEDO$11,029
- NURTEC ODT$10,318
- Cenobamate$5,550
- VNS - Sentiva$5,403
- VNS Therapy$4,253
- DYSPORT$1,511
- TYSABRI$150
- Briviact$130
- AIMOVIG$125
- BOTOX$123
- Fintepla$101
- VALTOCO$101
How this compares
$525,281 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 151 | $272,525 |
| AustedoDeutetrabenazine | 18 | $244,520 |
| Austedo XrDeutetrabenazine | 22 | $244,160 |
| QuliptaAtogepant | 89 | $132,708 |
| NuplazidPimavanserin Tartrate | 24 | $116,008 |
| AubagioTeriflunomide | 12 | $109,369 |
| UbrelvyUbrogepant | 51 | $84,666 |
| FycompaPerampanel | 53 | $76,243 |
| VimpatLacosamide | 38 | $61,304 |
| Nurtec OdtRimegepant Sulfate | 21 | $55,639 |
| Lamictal XrLamotrigine | 13 | $26,189 |
| BriviactBrivaracetam | 20 | $25,202 |
| GraliseGabapentin | 15 | $24,258 |
| LyricaPregabalin | 15 | $22,336 |
| KeppraLevetiracetam | 13 | $21,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $50,086 | $488,68040 claims |
| SK Life Science, Inc.Xcopri | $43,806 | $272,525151 claims |
| AbbVieQulipta, Ubrelvy | $91,228 | $217,374140 claims |
| Acadia Pharmaceuticals IncNuplazid | $653 | $116,00824 claims |
| SanofiAubagio | $406 | $109,36912 claims |
| UCB, Inc.Vimpat, Briviact, Nayzilam | $1,708 | $102,71773 claims |
| PfizerNurtec Odt, Lyrica, Dilantin | $8,149 | $83,55356 claims |
| Eisai Inc.Fycompa | $34,134 | $76,24353 claims |
| Almatica Pharma LLCGralise | $20 | $24,25815 claims |
| UCB SAKeppra | $134,782 | $21,77013 claims |
| Neurelis, Inc.Valtoco | $387 | $15,95116 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $314 | $13,73711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.
Other neurology in Fort Wayne
- Ajay GuptaFort Wayne$2.5M
- James StevensFort Wayne$1.5M
- Andrea HallerFort Wayne$793K
- Paul LaterFort Wayne$132K
- Christopher VachonFort Wayne$114K
- Thomas BanasFort Wayne$91K
- Fen Lei ChangFort Wayne$47K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.